Hengehold Capital Management LLC held its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,486 shares of the medical equipment provider’s stock at the end of the second quarter. Hengehold Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $319,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in ZBH. MARSHALL WACE ASIA Ltd purchased a new stake in Zimmer Biomet Holdings during the first quarter worth $38,621,000. Cibc World Markets Corp boosted its stake in Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock worth $2,565,000 after buying an additional 7,269 shares during the period. Caxton Associates LP purchased a new stake in Zimmer Biomet Holdings during the first quarter worth $403,000. Thrivent Financial for Lutherans boosted its stake in Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock worth $737,000 after buying an additional 450 shares during the period. Finally, Auxier Asset Management boosted its stake in Zimmer Biomet Holdings by 3.3% in the fourth quarter. Auxier Asset Management now owns 86,514 shares of the medical equipment provider’s stock worth $8,928,000 after buying an additional 2,750 shares during the period. 82.84% of the stock is currently owned by institutional investors and hedge funds.
Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down 0.93% on Friday, hitting $111.38. 1,036,099 shares of the company’s stock traded hands. The company has a market cap of $22.52 billion, a price-to-earnings ratio of 31.72 and a beta of 1.20. The firm’s 50-day moving average price is $122.63 and its 200 day moving average price is $121.15. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The company had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s revenue was up 1.1% compared to the same quarter last year. During the same period last year, the company earned $2.02 earnings per share. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/zimmer-biomet-holdings-inc-nysezbh-stake-held-by-hengehold-capital-management-llc-updated-updated-updated.html.
A number of analysts recently weighed in on ZBH shares. Goldman Sachs Group, Inc. (The) started coverage on shares of Zimmer Biomet Holdings in a report on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price objective on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Wells Fargo & Company cut shares of Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Finally, Morgan Stanley raised their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $136.90.
In related news, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.